Sotatercept denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for sotatercept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Sotatercept (Winrevair) as Duplicate Therapy

UnitedHealthcare may issue a duplicate-therapy denial for sotatercept (brand name Winrevair) when it identifies another agent on your medication record that it considers to treat pulmonary arterial hypertension (PAH) through the same or similar mechanism, and therefore classifies sotatercept as redundant. This denial can also occur due to administrative error — for example, if sotatercept is confused with another PAH drug on a prior authorization or claim record.

Sotatercept works through a distinct mechanism (activin signaling inhibition via an activin receptor fusion protein) that differs from established PAH drug classes such as endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin pathway agents, and soluble guanylate cyclase stimulators. Because the mechanism is genuinely different, a duplicate-therapy denial is often clinically inaccurate and worth contesting.

## Federal Appeal Framework

• Internal appeal (ERISA §503 / ACA §2719): You have the right to a full-and-fair internal review. Most plans allow 180 days from the denial notice.
• External review (ACA §2719): After exhausting internal appeals, you are entitled to independent external review. The window is approximately four months from final internal denial. Expedited external review is available when delay would seriously jeopardize your health — a real possibility in PAH.

## Appeal Process and Timeline

1. Obtain the denial letter and UHC's definition of "duplicate therapy" as applied in this case. 2. Have your prescriber prepare a written rebuttal explaining sotatercept's distinct mechanism relative to the drug(s) UHC identified as duplicates. 3. File the internal appeal with this letter and supporting documentation. 4. If denied internally, file for external review and request expedited processing given the serious nature of PAH.

## Documentation to Gather

• Diagnosis confirmation: Records establishing the PAH diagnosis, WHO functional class, and hemodynamic parameters from right-heart catheterization, confirming the severity and the clinical rationale for combination or add-on therapy.
• Current medication list: A complete annotated list of all PAH medications, with mechanism of action noted for each, demonstrating that no other activin signaling inhibitor is currently prescribed.
• Prescriber medical-necessity letter: A letter from the treating pulmonologist or cardiologist explaining sotatercept's unique mechanism, why it is not duplicative of any other agent the patient is receiving, and citing the applicable PAH guideline organization (e.g., the relevant AHA/ATS/CHEST guideline) by name.
• Chart documentation: Clinical notes documenting disease progression, functional class, and the rationale for adding sotatercept to the existing regimen.

## Criteria-Mapping Structure

Obtain UHC's coverage policy for sotatercept and its definition of duplicate therapy. For each criterion, map the specific chart fact that addresses it. Confirm that sotatercept's mechanism of action — as described in the FDA-approved prescribing label — is documented as distinct from every other PAH agent on the patient's active medication list. This mechanism comparison is the core of a successful duplicate-therapy rebuttal for sotatercept.